Results 221 to 230 of about 1,019,575 (429)

Alterations and mechanistic insights of gut microbiota and its metabolites in type 2 diabetes mellitus and Alzheimer's disease

open access: yesiMetaOmics, EarlyView.
This narrative review uniquely addresses how gut microbiota‐derived metabolites mediate overlapping pathologies of insulin resistance, neuroinflammation, and amyloidogenesis in type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD), proposing a framework for dual therapeutic targeting.
Guangyi Xu   +8 more
wiley   +1 more source

Mechanistic Insights and Pharmacological Approaches for Nitrogen and Sulfur Mustards and Their Implications as Therapeutic Agents

open access: yesJournal of Applied Toxicology, EarlyView.
ABSTRACT Nitrogen and sulfur mustards, often acting as vesicants, have significant consequences for public health. Skin is a common site for exposure to these vesicants that can result in considerable morbidity and mortality. Given that the treatment options are limited, new insights into the mechanisms for the toxicity of these vesicants that can be ...
Madison Owens   +3 more
wiley   +1 more source

A case of neuroleptic malignant syndrome on withdrawal of benzhexol [PDF]

open access: yes, 2010
The neuroleptic malignant syndrome is a rare and potentially lethal reaction which is usually associated with the use of medications with antidopaminergic properties.
Falzon, Stephanie   +2 more
core  

Allergenicity, Genotoxicity and Subchronic Toxicity Assessment of IgG Binding Protein LT Produced From Aspergillus oryzae

open access: yesJournal of Applied Toxicology, EarlyView.
ABSTRACT Gastrointestinal health is one of the fastest growing areas in the food and beverage industry, as its importance to overall health and well‐being is becoming increasingly recognized. Immunoglobulins play a key role in protecting the gastrointestinal tract, and nonbovine sources of immunoglobulins (including camel milk, which has a long history
Kirt R. Phipps   +8 more
wiley   +1 more source

Clinical Assessment of the Drug–Drug Interaction Potential of Omaveloxolone in Healthy Adult Participants

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Omaveloxolone is approved in the United States and the European Union for the treatment of patients with Friedreich ataxia aged ≥16 years. It is mainly metabolized by cytochrome P450 (CYP) 3A4 in vitro. Two drug–drug interaction studies (NCT04008186 and NCT05909644) were performed to evaluate (1) the effect of drug‐metabolizing enzymes (DMEs ...
Hamim Zahir   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy